Compatibility of injectable oxytocin and tranexamic acid: Exploring the possibilities for co-adminsitration

2. Postpartum haemorrhage (PPH) is a leading cause of maternal mortality. Healthcare providers need to manage PPH quickly and effectively. The WHO recommended a treatment bundle including oxytocin and tranexamic acid, which shows a 60% reduction in severe PPH. However, mixing of these compounds needs further investigation as preliminary results showed a significant loss of oxytocin when certain products were combined. This study showed impurities in these products to be the cause of the incompatibility. Importantly, the study revealed that pharmacopeial quality testing methods may not detect these impurities, posing challenges in identifying poor-quality products in low-resource settings.